Immunity Enhancement in Immunocompromised Gastrointestinal Cancer Patients with Allogeneic Umbilical Cord Blood Mononuclear Cell Transfusion

Figure 1

CONSORT diagram of patient distribution. A total of 37 patients were excluded from the clinical data, including 16 in the trial group and 21 in the control group, because these patients did not finish all necessary immunoassays or accepted new courses of radiotherapy and/or chemotherapy during the 48-week follow-up.